ARTICLE | Distillery Therapeutics
Other
June 20, 2017 4:20 PM UTC
Patient sample and mouse studies suggest inhibiting COL6A1 could help treat hyaline fibromatosis syndrome (HFS), which is caused by ANTXR2 mutations. In patients, levels of COL6A1 were higher in HFS s...
BCIQ Company Profiles